Monument Tx is an independent UK based biotechnology company formed in 2019 as a spin-out from Cambridge Cognition.
Monument Tx develops products to treat serious diseases of the central nervous system. Our precision medicine approach utilises proprietary digital biomarkers to reduce heterogeneity and identify patients with homogenous underlying neurobiology, which are then matched with appropriately targeted compounds.
Using biomarkers to more accurately identify patients with a disease sub-type most likely to respond to a particular treatment is already successfully used in the treatment of cancer. Now Monument Tx brings digital biomarkers to neuroscience drug development to provide a precision medicine approach in clinical areas of high unmet need.
Contact us to learn more about our company and solutions.
“We want to do for psychiatry and neurology what biomarker testing has done for the diagnosis and treatment of cancer”
The Monument Tx Leadership Team